Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stefania Oliva
Observed names:
Oliva, Stefania,
S. Oliva
Institution:
Sapienza University of Rome
Observed institutions:
University of Siena,
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
Fondazione Gimema Onlus,
Azienda Ospedaliera Sant'Andrea,
University of Turin,
Sapienza University of Rome
show all 6
ORCID:
0009-0009-7274-3552
Observed ORCID:
0009-0009-7274-3552
OpenAlex ID:
A5102895357
Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study
2017
·
Cavo, Michele
, Hájek, Roman
, et al.
·
Pure Amsterdam UMC
·
47
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
2024
·
Bachisio Ziccheddu
, Claudia Giannotta
, et al.
·
Blood Cancer Journal
·
35
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
2023
·
Stefania Oliva
, Elisa Genuardi
, et al.
·
EClinicalMedicine
·
34
PDF
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
2022
·
Luca Bertamini
, Giuseppe Bertuglia
, et al.
·
Frontiers in Oncology
·
32
PDF
Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
2018
·
Enrique M. Ocio
, Paula Rodriguez Otero
, et al.
·
Blood
·
23
Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients
2019
·
Stefania Oliva
, Elisa Genuardi
, et al.
·
Blood
·
22
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age
2013
·
Alessandra Larocca
, Federica Cavallo
, et al.
·
Blood
·
22
Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity
2020
·
Luca Bertamini
, Mariella Grasso
, et al.
·
Blood
·
20
Introducing Telemedicine in Italy: Citizens’ Awareness of a New Healthcare Resource
2023
·
Francesca Gallè
, Stefania Oliva
, et al.
·
Healthcare
·
19
PDF
Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.
2017
·
Stefania Oliva
, Davine Hofste op Bruinink
, et al.
·
Journal of Clinical Oncology
·
19
Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM).
2020
·
Stefania Oliva
, Elisa Genuardi
, et al.
·
Journal of Clinical Oncology
·
17
Collective Catering Activities and Official Controls: Dietary Promotion, Sustainability and Future Perspectives
2023
·
Vincenzo Marcotrigiano
, Giacomo Domenico Stingi
, et al.
·
Healthcare
·
15
PDF
MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial
2019
·
Elena Zamagni
, Cristina Nanni
, et al.
·
Blood
·
15
A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation
2017
·
Enrique M. Ocio
, Sara Bringhen
, et al.
·
Blood
·
13
A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma
2013
·
Sara Bringhen
, Chiara Cerrato
, et al.
·
Blood
·
13
Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial
2020
·
Stefania Oliva
, Elisa Genuardi
, et al.
·
Blood
·
12
CD38 and Antibody Therapy: What Can Basic Science Add?
2016
·
Fabio Malavasi
, Antonella Chillemi
, et al.
·
Blood
·
12
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients
2016
·
Sara Bringhen
, Valeria Magarotto
, et al.
·
Blood
·
9
Sleep quality among Italian university students: the UnSleep multicenter study.
2025
·
Francesca Gallè
, Fabiano Grassi
, et al.
·
Annali di Igiene Medicina Preventiva e di Comunità
·
8
PDF
Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).
2020
·
Enrique M. Ocio
, Paula Rodríguez Otero
, et al.
·
Journal of Clinical Oncology
·
8
Early Mortality in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Agents
2015
·
A. Larocca
, S. Bringhen
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
8
Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients
2014
·
Lenka Kubiczkova-Besse
, Daniela Drandi
, et al.
·
Blood
·
8
Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
2023
·
Enrique M. Ocio
, Sara Bringhen
, et al.
·
HemaSphere
·
6
Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy
2016
·
Stefania Oliva
, Manuela Gambella
, et al.
·
Blood
·
6
A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis
2024
·
Claudia Bellofiore
, Pietro Benvenuti
, et al.
·
Hematological Oncology
·
5
Show more works
View as search
Works count:
50
Citation count:
463
H-index:
13
I10-index:
17
Year
Topic
Type